117,913 Shares in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Bought by Windmill Hill Asset Management Ltd

Key Points

• Windmill Hill Asset Management Ltd acquired a new stake in Centessa Pharmaceuticals PLC, purchasing 117,913 shares valued at approximately $1.7 million, making it the 14th largest position in their portfolio.
• Insider trading activity included CEO Saurabh Saha selling 55,000 shares, representing a 19.93% decrease in his holdings, as well as a decrease in share ownership by another insider.
• Analysts have a consensus rating of "Moderate Buy" for Centessa Pharmaceuticals, with various price targets ranging from $28.10 to $38.00 set by multiple research firms.

Windmill Hill Asset Management Ltd acquired a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 117,913 shares of the company's stock, valued at approximately $1,696,000. Centessa Pharmaceuticals comprises approximately 0.5% of Windmill Hill Asset Management Ltd's investment portfolio, making the stock its 14th biggest holding. Windmill Hill Asset Management Ltd owned about 0.09% of Centessa Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth about $31,000. Barclays PLC lifted its stake in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Centessa Pharmaceuticals during the fourth quarter worth approximately $162,000. OMERS ADMINISTRATION Corp purchased a new stake in Centessa Pharmaceuticals during the fourth quarter worth approximately $171,000. Finally, Bank of New York Mellon Corp purchased a new stake in Centessa Pharmaceuticals during the first quarter worth approximately $147,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Price Performance

Shares of CNTA traded up $0.08 during midday trading on Wednesday, reaching $15.29. The stock had a trading volume of 176,921 shares, compared to its average volume of 923,937. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.10 and a 52 week high of $19.09. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37 and a quick ratio of 14.37. The firm's 50 day moving average price is $13.65 and its 200-day moving average price is $14.39. The company has a market capitalization of $2.04 billion, a P/E ratio of -8.47 and a beta of 1.45.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.15. On average, analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CNTA. Truist Financial began coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $30.00 price target for the company. Needham & Company LLC began coverage on Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price target for the company. Oppenheimer started coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price objective for the company. Wall Street Zen raised Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Chardan Capital started coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set a "buy" rating and a $30.00 target price on the stock. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.10.

Insider Activity

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $15.92, for a total value of $875,600.00. Following the transaction, the chief executive officer directly owned 221,017 shares of the company's stock, valued at $3,518,590.64. This represents a 19.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $15.56, for a total value of $155,600.00. Following the transaction, the insider directly owned 122,279 shares in the company, valued at approximately $1,902,661.24. This represents a 7.56% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 222,311 shares of company stock valued at $3,074,294. 7.09% of the stock is currently owned by company insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.